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Objective: In most settings, less than 25% of patients with treatment-resistant schizophrenia 
receive clozapine, the only medication proven effective for treatment-resistant schizophrenia. 
Therefore, a business case analysis was conducted to assess whether increasing clozapine 
utilization for treatment-resistant schizophrenia in a health care system would result in direct 
health care cost savings. 
Methods: Veterans with treatment-resistant schizophrenia who were treated in the Veterans 
Health Administration (VHA) were studied. Treatment response, suicides, adverse drug reactions 
(and associated mortality), and effects on inpatient hospitalization related to clozapine were 
derived from a systematic review of published studies. A one-factor sensitivity analysis and a 
probabilistic sensitivity analysis (PSA) with Monte Carlo simulation were conducted to calculate 
the cost-benefits of increased clozapine utilization. 
Results: Despite monitoring costs, in the base case analysis, the VHA would save $22,444 per 
veteran with treatment-resistant schizophrenia over the first year of clozapine therapy, primarily 
from 18.6 fewer inpatient days per patient. If current utilization was doubled, and 50% of those 
veterans continued clozapine treatment for one year, VHA would save an estimated $80 million. 
Cost savings were most sensitive to the proportion of treatment-resistant patients who received 
clozapine, decrease in inpatient days, cost of inpatient stays, clozapine response rate, and number 
of patients with treatment-resistant schizophrenia. In the PSA, initiation of clozapine for all VHA 
patients with treatment-resistant schizophrenia who were not currently treated with clozapine 
would save at least $290 million in 95% of simulations. 
Conclusions: Increased clozapine utilization would result in net cost savings for the VHA. 
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Clozapine is the only treatment that has been proven effective for treatment-resistant 
schizophrenia (1–11) and the only treatment approved by the U.S. Food and Drug 
Administration (FDA) to decrease suicidal behavior associated with schizophrenia (7). However, 
clozapine is associated with significant adverse drug reactions (ADRs), requiring compliance 
with an FDA-mandated risk mitigation and evaluation strategy program (7). Given the 
complexity of the program—which requires patient, prescriber, and pharmacy registration; 
weekly blood draws; and seven-day fills for the first six months of therapy—clozapine is 
prescribed for only a minority of patients with treatment-resistant schizophrenia (12–17). 
Despite evidence demonstrating clozapine’s benefits, use of clozapine in the United States has 
steadily declined since the introduction of other second-generation antipsychotics to the U.S. 
market (12,13). Within the Veterans Health Administration (VHA), 4% of patients with 
schizophrenia receive clozapine (13). Low clozapine utilization is also reported in non-VHA and 
international treatment settings (11,14–16). Considering that 20% to 30% of patients have 
treatment-resistant schizophrenia, the low rate of utilization of clozapine implies that 82% to 
88% of patients with treatment-resistant schizophrenia are receiving less effective antipsychotics. 
Given clozapine’s unique effectiveness for treatment-resistant schizophrenia and its potential to 
decrease suicidal behaviors and utilization of more costly forms of care, increasing clozapine 
utilization could lead to significant cost savings, despite increased monitoring and contact with 
the health care system. Therefore, we conducted a cost-benefit analysis with data obtained from a 
medical literature review to simulate potential cost savings associated with increasing clozapine 
utilization within the VHA. The hypothesis was that potential cost savings, mostly from 
decreased inpatient hospital days, would constitute a case for expanding clozapine utilization, 
even if achieving such a goal entailed considerable costs and effort. 
Methods 
Model Design 
We developed a simulation on the basis of data from the medical literature to estimate costs 
associated with varying degrees of clozapine utilization. The decision model is a tree structure 
comparing the choice of whether or not to use clozapine for a treatment-resistant patient at a 
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single decision node over a one-year time horizon, calculated from the perspective of the VHA 
(18). In the clozapine arm, subsequent branch points were event nodes that represent likelihood 
of response, risk of completed suicide, and risk of serious ADRs resulting in clozapine 
discontinuation (Figure 1). In the clozapine arm, nonresponse was assumed to lead to clozapine 
discontinuation. We modeled only serious ADRs (agranulocytosis, seizures, diabetic 
ketoacidosis, myocarditis, and ileus) that have been attributed to clozapine use (7). [Figure 1] 
In the nonclozapine arm, suicide risk was modeled at a single branch point, and we assumed that 
there would be no ADRs, even though other medications cause ADRs. This is a simplifying 
assumption, but a conservative model was chosen to decrease the likelihood of overestimating 
the benefits of clozapine treatment. Costs of inpatient and outpatient psychiatric care, laboratory 
monitoring, and health care expenditures related to ADRs were incorporated into the clozapine 
arm. Differential mortality risks from completed suicides between the clozapine and 
nonclozapine arms and aggregate risks of mortality from clozapine-related ADRs were 
calculated. 
This study was exempted from review by the XXX Institutional Review Board. 
Model Inputs 
Response to clozapine. 
We conducted a systematic literature search of MEDLINE articles indexed between January 1, 
1985, and June 30, 2015, for studies using the terms “clozapine” AND “refractory 
schizophrenia” OR “treatment resistant” OR “resistant schizophrenia.” Thirty-nine articles were 
evaluated for number of persons given clozapine and clinical response rate (4,19–56). If these 
values could not be ascertained from the text or if the subjects were under 18 years of age, the 
article was excluded. Response was most commonly defined as a 20% improvement in baseline 
score on the Brief Psychiatric Rating Scale, but inclusion of an article was not conditional on this 
definition. Of the 39 identified articles, 31 articles comprising 2,571 clozapine patients were 
included (4,19–45,47–49) [see online supplement]. We calculated a pooled clozapine response 
rate of 51%. 
Suicide rate. 
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Completed suicide rate was calculated as the product of the annual suicide rate for the U.S. 
general population ages 35–64, the standardized mortality ratio from suicide for schizophrenia, 
and a published hazard ratio of suicide for male veterans with schizophrenia (57–60). The effect 
of clozapine on suicide risk was determined on the basis of a meta-analysis of five studies that 
calculated the relative risk of completed suicide associated with use of clozapine. The relative 
risk of completed suicide was 2.90 among patients who did not use clozapine compared with 
those who used clozapine (61). For this model, reduction in the risk of suicide was applied only 
among clozapine responders; nonresponders were assumed to have a similar risk of suicide as 
patients receiving nonclozapine antipsychotics. 
Clozapine-related ADRs. 
Pooled risks and mortality of the clozapine-related ADRs were calculated from studies identified 
through the literature review and the clozapine-prescribing information (7,62–64). A pooled risk 
of clozapine-related seizures and subsequent risk of discontinuation were calculated from an 
analysis of the clozapine patient management system database (64). 
Costs of treatment. 
Costs for the first year of clozapine treatment were determined to be the cost of laboratory 
monitoring and follow-up visits plus the VHA cost of clozapine tablets. On the basis of current 
guidelines for monitoring, there are a total of 39 visits over the course of one year of treatment 
(weekly for six months and biweekly for the next six months) (7). We used the pricing schedule 
used by the Centers for Medicare and Medicaid Services for the 2015 CPT code for a complete 
blood cell count with differential cell count and for the evaluation and management code for a 
level II visit with a psychiatrist (65). Patients were assumed to be reimbursed $20 for travel costs 
by VHA for each follow-up visit. Clozapine costs in the base case were for a total daily dose of 
600 mg, based on 2015 VHA pricing of 41 cents for a 100-mg tablet. 
Costs of ADRs. 
The estimated cost of the ADRs was the sum of annual direct health care costs (prescriptions, 
inpatient treatment, emergency services, outpatient treatment, and office-based medical visits). 
Adults with relevant three-digit ICD-9-CM codes and Clinical Classification Software codes 
were identified through examination of the Medical Expenditure Panel Survey from 2002 to 
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2011 for condition-related annual health care expenditures (66). For diabetic ketoacidosis, costs 
were for a single inpatient hospitalization rather than yearly costs (67). 
Inpatient psychiatric stays and costs. 
The length of inpatient stay was calculated from a pooled, random-effects meta-analysis of seven 
studies identified in the systematic review (33,34,36,38,39,68,69) [see online supplement]. These 
studies evaluated the impact of clozapine therapy on hospital days, using either a prepost 
comparison or a comparison between hospital days for intervention and control patients. The cost 
of an inpatient stay at a VA hospital was estimated at $1,414 per day (13). 
Treatment-eligible population. 
In 2009, a total of 87,000 veterans had schizophrenia or schizoaffective disorder (13). Although 
20% to 30% of patients are reported to have treatment-resistant schizophrenia, we assumed that 
20% of patients, an estimated 18,000 veterans, had treatment-resistant schizophrenia (1). 
Assuming that the 3.6% of veterans with schizophrenia already treated with clozapine had 
treatment-resistant schizophrenia, we estimated an additional 14,400 veterans with treatment-
resistant schizophrenia would be eligible for a clozapine trial. 
Cost Reporting 
For each parameter, costs that were not already in 2015 U.S. dollars were inflated to 2015 U.S. 
dollars by calculating the rate of medical inflation from the Consumer Price Index (CPI) between 
the year in which the parameter was reported and 2014 (last available year of the CPI) and then 
adjusting again by the average yearly rate of medical inflation from 2010 to 2014 (70). 
Analysis 
This analysis was a cost-benefit model, comparing costs and monetizing benefits associated with 
clozapine use and nonuse in treatment-resistant schizophrenia. The deterministic base case model 
used the parameter estimates for the model inputs detailed above to determine the difference in 
costs for treatment-resistant schizophrenia between clozapine treatment and nonuse of clozapine. 
In the clozapine arm, the costs of treatment, ADRs, and inpatient stays were summed. In the 
nonclozapine arm, it was assumed that ADRs did not occur and medications had no costs, so the 
costs reflected inpatient stays. Mortality was estimated by the effect of clozapine on suicide 
among veterans and anticipated mortality from serious ADRs (61–63). The business case for 
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clozapine was broadened by multiplying the results over the treatment-eligible population within 
the VHA. 
Several assumptions were made for model variability. Costs of expenditures directly 
attributable to clozapine use (prescriptions, laboratory monitoring, office visits, and treatment of 
serious ADRs) were not included in the control arms. Health care expenditures unrelated to 
clozapine effects were assumed to be identical in the two arms to prevent needlessly 
complicating the model; these expenditures included metabolic monitoring, which is 
recommended for all patients on antipsychotics. Benefits of reduced inpatient stay and 
diminished incidence of completed suicide were applied only for clozapine responders. Costs of 
clozapine treatment were incurred for the entire year for clozapine responders and were prorated 
until day of discontinuation for nonresponders. All costs for persons who died by suicide were 
curtailed at the day of suicide. ADR costs were prorated from the day on which the ADR 
occurred until the end of the year, with the exception of diabetic ketoacidosis, which was 
assumed to be a single event. In the base case deterministic model, suicide, clozapine 
discontinuation due to nonresponse, and ADRs occurred at six months, the midpoint of the year 
(day 183). Among clozapine responders, the ADRs were assumed to lead to discontinuation, 
except seizures, in which case we used published rates of discontinuation of clozapine following 
a seizure to estimate the proportion of patients who would continue clozapine (64). For clozapine 
nonresponders, all ADRs were assumed to result in drug discontinuation. 
To incorporate uncertainty, one-factor sensitivity analyses and a probabilistic sensitivity 
analysis (PSA) with Monte Carlo simulation were calculated (71). In the factor analysis, we 
varied the range of input parameters by 20% in each direction from the base case, except the 
proportion of treatment-resistant schizophrenia patients initiated on clozapine, which were varied 
from 20% to 80%. We then evaluated the relative influence of high and low values for each input 
on cost savings for the health care system. For the PSA, method of moments were used to fit 
probability parameters on beta distributions, relative risk and hazard ratios on log normal 
distributions, and event days (ADRs, clozapine discontinuation, and suicide). Fixed costs (lab 
monitoring, veteran travel, and psychiatrist visits) were varied on uniform distributions. Gamma 
distributions were used to fit aggregate ADR costs, and Poisson distributions were used to fit 
inpatient days (Table 1). Random numbers generated output values within distributional 
assumptions. Simulated cost outcomes were determined for the entire health care system, with 
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1,000 replications each for initiation of clozapine among 20%, 40%, 60%, and 80% of patients 
with treatment-resistant schizophrenia. The last of these proportions would equate to 100% 
clozapine use because it would be added to the current rate of use of clozapine for treatment-
resistant schizophrenia, which is approximately 20%. Simulations and analysis were performed 
by using Excel 2010 and Stata, version 13, software packages. 
Results 
Cost Savings 
If 20% of veterans with treatment-resistant schizophrenia initiated clozapine, the one-year costs 
to the VHA would decrease by a mean of $22,444 per patient treated with clozapine. Savings 
were driven primarily through an average reduction of 18.6 inpatient hospital days. If current 
utilization was doubled and 50% of those veterans continued clozapine treatment for one year, 
the VHA would accrue an estimated cost savings of $80 million (Table 2). 
ADRs 
An additional 743 serious ADRs would occur in year 1 if all veterans with treatment-resistant 
schizophrenia who had previously not been treated with clozapine initiated clozapine treatment. 
If only 20% of those veterans began treatment with clozapine, an additional 149 serious ADRs 
would occur (Table 2). 
Deaths 
If all veterans with treatment-resistant schizophrenia who had not been treated with clozapine 
later initiated clozapine, 19 suicides would be averted annually, and there would be a total of 18 
additional deaths, three due to clozapine-related agranulocytosis and 15 due to ileus. If only 20% 
of veterans with treatment-resistant schizophrenia who had not previously initiated clozapine 
began treatment with clozapine, there would be three deaths due to clozapine-related ADRs and 
three fewer suicides in the clozapine group versus the nonclozapine group. Greater increases in 
clozapine use would lead to more lives saved by suicide prevention than lives lost to clozapine-
associated ADRs. 
Sensitivity Analysis 
One-way sensitivity analysis was performed, varying each of the model inputs across a plausible 
range to evaluate the input’s influence on our findings. Cost savings were most sensitive to 
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changes in the proportion of patients with treatment-resistant schizophrenia who received 
clozapine (92% of the swing in range of costs), reduction in inpatient days (2%), cost of inpatient 
stay (2%), rate of response to clozapine (2%), and number of patients with treatment-resistant 
schizophrenia (2%) (Figure 2). Costs associated with laboratory monitoring, ADRs, outpatient 
visits, and travel had negligible impact on costs for the payer. Probabilistic sensitivity analysis 
confirmed that increasing the number of patients with treatment-resistant schizophrenia receiving 
clozapine would result in incremental cost savings. Assuming a baseline rate of 20% for 
clozapine utilization, cost savings increased to $323,188 million when 100% of patients with 
treatment-resistant schizophrenia were prescribed clozapine. 
Figure 3 shows the cost implications of initiating clozapine for 20% to 80% of patients with 
treatment-resistant schizophrenia (representing 100% utilization at beginning of year 1, including 
current users). A relatively modest change, doubling utilization from 20% to 40% of eligible 
patients, would lead to cost savings of more than $80 million in the first year of treatment. In 
95% of simulations, increasing clozapine utilization from 20% to 40% of eligible patients saved 
a minimum of $72 million in the first year. Initiation of clozapine for all VHA patients with 
treatment-resistant schizophrenia who were not currently treated with clozapine would save at 
least $290 million in 95% of simulations. 
Discussion 
Clozapine has repeatedly demonstrated superiority to other antipsychotics for treatment-resistant 
schizophrenia, but it is underutilized. Therefore, we simulated the effects of increasing clozapine 
utilization for patients with treatment-resistant schizophrenia. Doubling the proportion of 
patients with treatment-resistant schizophrenia who received clozapine from 20% to 40% would 
save $80 million for the VA, without considering any value accruing to patients from improved 
outcomes. In addition, despite the much-feared adverse effects of clozapine, the increase in 
ADR-related mortality associated with clozapine would be more than offset by suicide 
prevention. 
The benefits of increased clozapine utilization may have been underestimated because of 
several assumptions. First the model assumed that 20% of patients with schizophrenia have 
treatment-resistant schizophrenia, although many studies have estimated a rate as high as 30% 
(1). Second, the costs of clozapine treatment are substantially higher in the first year compared 
with later years because of a need for more office visits and laboratory monitoring. After the first 
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year, the continued costs of clozapine treatment are more similar to those of other antipsychotics, 
but the benefits of clozapine treatment continue to accrue. In addition, this model assumed that 
treatment with other antipsychotics did not result in serious ADRs or include prescription or 
other treatment costs. Thus it is possible savings could be higher than reported in this study. 
Our analyses had several important uncertainties. First, it was difficult to estimate the 
incidence and costs of obesity and diabetes risk and the expected increased risk in cardiovascular 
mortality and morbidity associated with use of clozapine. Some comparator agents have similar 
risks, whereas most have substantially lower risks than clozapine (72). In addition, studies have 
reported mixed effects of clozapine on mortality (73–75). As such, cardiometabolic ADRs were 
not included in the analyses. Second, it should be remembered that extrapolation of cost savings 
to subsequent years and to use outside the VHA is uncertain. Third, some of the studies 
providing evidence for clozapine benefits were conducted years ago and thus may be less 
relevant to current practice. Finally, the base model assumed a reduction of 30 inpatient days in 
the first year. Although that may seem extreme in an era of shortened hospitalizations, the 
average length of stay for schizophrenia both within and outside the VHA in 2009 and 2011 was 
approximately 21 days, and patients with treatment-resistant schizophrenia averaged three 
hospitalizations per year (13,76). In addition, studies indicate that more severe illness, as would 
be expected with treatment-resistant schizophrenia, further increases the length of stay (76). Thus 
it is reasonable to assume that clozapine would be associated with 30 days of inpatient 
hospitalization. Varying the analyses by limiting the number of days of hospitalization avoided 
to seven still resulted in cost savings [see online supplement]. 
This study had important strengths. A number of underlying assumptions suggest that, if 
anything, benefits of increased clozapine utilization have been underestimated. In addition, much 
is known about the improved outcomes, adherence, and persistence rates associated with 
clozapine treatment (75,76). However, the study also had some limitations. First, all the data 
were not from the VHA or specifically related to treatment-resistant schizophrenia. For example, 
the suicide rate was not based on rates for schizophrenia populations with treatment-resistant 
disease, given the lack of data on suicide among patients with treatment-resistant schizophrenia. 
Second, rates of response, ADRs, and costs associated with use of clozapine were based on the 
published literature and may not accurately reflect real-world systems. Third, dispensing costs 
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were not included, given that we found no estimates that included the added cost of maintenance 
and oversight of the VHA clozapine registry. 
Clozapine monitoring guidelines have recently changed. It is unlikely that these changes will 
have a significant impact on cost of monitoring, but the possibility cannot be excluded. In 
addition, monitoring of clozapine serum concentrations is recommended by some guidelines. 
Because clozapine serum concentrations are not routinely monitored, we excluded these costs 
from our analyses. If completed, such monitoring would be expected to increase clozapine costs. 
It is important to note the circumscribed nature of the study. This study was not a cost-utility 
analysis and, therefore, did not formally model patient-related outcomes, such as health-related 
quality of life. Instead, we opted to conduct a simpler business case analysis from the VHA 
perspective, including direct health care costs and veterans’ travel costs but excluding indirect 
costs, such as caregiver time and missed work. It should be noted that the value to society from 
increased clozapine utilization for treatment-resistant schizophrenia would greatly exceed the 
cost savings we reported here because patients and, presumably, their families prefer that the 
symptoms of schizophrenia be well controlled (77). However, payers are likely most responsive 
to a business case analysis, which is why we chose this approach. 
In a separate study, we found that some relatively straightforward strategies were associated 
with higher clozapine utilization within the VHA (X). Among these are having a dedicated 
clozapine clinic; ensuring that the clinic has sufficient capacity to accommodate all patients with 
treatment-resistant schizophrenia and adequate staffing levels by nonphysicians, including 
registered nurses and pharmacists; and providing transportation to appointments for patients 
using clozapine. Although these strategies are allowable under VHA rules and regulations and 
are currently used at some sites, they are not without cost. 
It is hoped that this study provides an impetus to make these relatively straightforward, if not 
inexpensive, changes. Extrapolating from our findings, an average-sized VHA site (managing 
700 schizophrenia patients) could expect to have 140 patients with treatment-resistant 
schizophrenia. Increasing the proportion of patients with treatment-resistant schizophrenia who 
are treated with clozapine from 20% to 40% would save the facility more than $625,000 in the 
first year alone. It is difficult to imagine that the cost of implementing our recommendations 
could approach this figure. Thus, even a modest increase in clozapine utilization, achieved at a 
very high cost, could still result in a net cost savings for the VHA. 
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Conclusions 
This study found that modest increases in clozapine utilization could yield significant cost 
savings. It is very unusual to have the opportunity to save money while improving patient 
outcomes, particularly in such a vulnerable population. Our results suggest that the VHA should 
strongly consider initiatives, possibly based on practices already used by high-performing sites, 
to substantially increase clozapine utilization for treatment-resistant schizophrenia. 
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FIGURE 1. Outcomes of a decision model involving whether to initiate clozapine for a patient with treatment-resistant schizophrenia
a 
 
a
ADR, adverse drug reaction 
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FIGURE 2. Effects of varying the model inputs on the cost of clozapine care
a 
 
           Input      Cost Impact  
 
 
a
Input parameters were varied from the base case by 20% in each direction, except proportion of patients with treatment-resistant 
schizophrenia who were treated with clozapine, which varied from 20% to 80%. Reduced inpatient days were prorated for probability 
clozapine response rate. Rates of adverse drug reactions (ADRs), suicide, clozapine discontinuation, costs of ADRs, and laboratory 
monitoring had smaller impacts. 
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FIGURE 3. Estimated one-year VHA-wide savings and mortality associated with incremental 
gains in clozapine utilization among veterans with treatment-resistant schizophrenia
a 
 
a
Bars indicate mean, 5th, and 95th percentiles from 1,000 simulations for each incremental 
increase of 20%. 
∆ non-clozapine suicides 
◊ clozapine suicides 
o clozapine mortality from ADRs 
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TABLE 1. Adjustment of base case values during sensitivity analyses of the cost-benefits of 
increased clozapine utilization among veterans with treatment resistant schizophrenia
a
 
Variable Base case SD Distribution Notes 
Veterans with treatment-
resistant schizophrenia 
18,000  Uniform 2009 VHA estimate of ~90,000 
patients with schizophrenia  20% 
rate of treatment-resistant 
schizophrenia (13) 
 Proportion initiated 
clozapine treatment 
.20  Uniform Assumption 
 Probability of clozapine 
response 
.510 .01 Β Pooled meta-analysis of 31 studies 
(4,19–45,47–49) [see online supplement] 
Probability of completed 
suicideb 
.003  Β,, log 
normal 
U.S. suicide rate for ages 35–64  
SMR for suicides among persons with 
schizophrenia  HR for suicides 
among male patients with 
schizophrenia (57–60) 
Completed suicide rate 
given clozapine response 
[completed 
suicide/clozapine 
response]) 
.34 .8 Log normal 1/RR  (61)c 
Probability of ADR 
(clozapine arm only) 
    
 Agranulocytosis .005 .0002 Β, log 
normal 
Calculated from Cohen et al., 2012 
(63) 
 Myocarditis .0001 .000 β Calculated from Cohen et al., 2012 
(63) 
 Ileus .004 .0004 β Calculated from Cohen et al., 2012 
(63) 
 Seizures .032 .003 β Calculated from Cohen et al., 2012 
(63) 
 Diabetic ketoacidosis .0001 .000 β Calculated from Cohen et al., 2012 
(63) 
Probability of 
discontinuation of 
clozapine due to seizures 
.352 046 β Calculated from Cohen et al., 2012 
(63) 
Probability of mortality 
due to ADR 
.28 .28 β Calculated from Cohen et al., 2012 
(63) 
 Myocarditis   β  
 Agranulocytosis .03 .007 β Calculated from Cohen et al., 2012 
(63) 
 Ileus .20 .036 β Calculated from Cohen et al., 2012 
(63) 
 Diabetic ketoacidosis .03 .04 β Calculated from Cohen et al., 2012 
(63) 
Fixed costs ($)d     
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 Lab monitoring (event) 10.58  Uniform WBC; CPT G0306 (CMS 2015 Lab 
Diagnostic Fee Schedule, global, 
nonfacility) (64) 
 Psychiatrist visit 43.98  Uniform CPT 99212 (CMS 2015 Physician Fee 
Schedule, global, nonfacility) (64) 
 Veteran travel (event) 20.00  Uniform Assumption 
 Clozapine treatment 
(day) 
2.46  Uniform 100-mg tablet, 600 mg/day (VHA 
VISN 1 costs) 
 Inpatient stay (day) 1,413.70  Uniform 2009 VHA estimate (2015 $) 
Cost for ADR (2015 $)     
 Seizures (year) 1,621.62 245.75 γ MEPS 2002–2011 for adults (ICD-9 
code 345) (65) 
 Myocarditis (year) 3,695.89 934.70 γ MEPS 2002–2011 for adults (ICD-9 
code 422) (65) 
 Agranulocytosis (year) 2,428.31 1,641.52 γ MEPS 2002–2011 for adults (ICD-9 
code 288) (65) 
 Ileus (year) 6,796.33 1,234.79 γ MEPS 2002–2011 for adults >18 
(ICD-9 code 560 (65) 
 Diabetic ketoacidosis 
(single hospitalization) 
20,141.34 20,415.43 γ (67) 
Day of suicide 183  Uniform Assumption 
Day of discontinuation of 
clozapine 
183  Uniform Assumption 
Day of ADR (clozapine 
arm) 
183  Uniform Assumption 
Inpatient days 138  Poisson Pooled analysis of 7 studies 
(33,34,36,38,39,68,69) [see online 
supplement] 
Reduction in inpatient 
days among clozapine 
responders 
–37e  Poisson Unstandardized mean difference in 
inpatient days of 7 studies 
(33,34,36,38,39,68,69) [see online 
supplement] 
a
The base case used assumed or estimated mean values. SDs were used to calculate γ and β  
distributional parameters for probabilistic sensitivity analysis. Abbreviations: ADR, adverse drug 
reaction; CMS, Centers for Medicare and Medicaid Services; HR, hazard ratio; MEPS, Medical 
Expenditure Panel Survey; RR, relative risk; SMR, standard mortality ratio; VISN, Veterans 
Integrated Service Network; and WBC, white blood cell count 
b
The probability of suicide among veterans with treatment-resistant schizophrenia was a function 
of three individual parameters with distributional properties of mean and standard deviation. The 
SD variance was calculated from product of component inputs (SMR, HR, and incidence). 
c
The suicide rate for clozapine was calculated as the reciprocal of the rate of suicide prevention 
in the article by Hennen and Baldessarini (61). 
d
Fixed costs did not have an SD but were varied on uniform distributions with a range of ±20%. 
e
The SD was the mean for Poisson distribution.) 
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TABLE 2. Simulated outcomes from doubling baseline rates of clozapine utilization at the VHA 
for one year
a
 
Outcome Base case 
Simulated outcome (percentile) 
Mean 5th 95th 
Aggregate cost and 
utilization 
    
 Cost ($)     
  Control arm 700,410,000 695,541,000 633,082,000 757,851,000 
  Clozapine arm 619,613,000 615,697,000 560,652,000 671,316,000 
 Cost savings ($) 80,797,000 79,845,000 72,406,000 87,685,000 
 Inpatient days     
  Control arm 495,000 492,000 447,920 536,000 
  Clozapine arm 429,000 426,000 388,000 464,000 
 Inpatient days saved 67,000 66,000 60,000 72,000 
 Clozapine responders 1,787 1,794 1,629 1,964 
Adverse drug reaction 
(ADR)b 
    
 Seizures 116 115 94 137 
 Agranulocytosis 16 16 10 23 
 Myocarditis <1 <1 0 1 
 Ileus 16 16 9 23 
 Diabetic ketoacidosis <1 <1 0 2 
Mortality     
 Suicides (control arm) 11 11 6 17 
 Suicides (clozapine arm) 8 8 3 12 
 Deaths due to ADRs     
  Agranulocytosis <1 <1 0 2 
  Myocarditis <1 <1 0 1 
  Ileus 3 3 1 6 
  Diabetic ketoacidosis <1 <1 0 1 
a
Estimates are incremental costs, ADRs, and mortality associated with doubling estimated 
current clozapine use (deterministic base case analysis). Results are from the probabilistic 
simulation of incremental costs of clozapine initiation (clozapine arm) and noninitiation (control 
arm) associated with initiating clozapine for an additional 20% of the estimated 18,000 (±10%) 
veterans with treatment-resistant schizophrenia who were not currently receiving clozapine. 
b
Clozapine arm only. Seizures were assumed to be nonfatal. 
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Online Supplemental Material 
Table 1: Studies included in meta-regression 
Author Year Response 
% 
Total Trial 
Length(wks) 
Comments 
Small19 1987 40% 38 
 
Treatment-resistant schizophrenia 
and non-treatment-resistant 
schizophrenia - 55% response 
Kane4 1988 30% 134 6 
 
Mattes20 1989 57% 14 Up to 104 
Based on 8 did substantially better 
on clozapine 
Davidson21 1993 50% 28 5 
 
Kuoppasalmi22 1993 67% 103 26 
Based on statement "More than 2/3 
improved” 
Breier23 1993 60% 30 26 
 
Littrel24 1994 48% 42 12 
 
Lieberman25 1994 50% 66 52 
Treatment-resistant schizophrenia+ 
additional 18 patients not tolerant of 
other antipsychotics 
Szymanski26 1994 30% 10 
  
Honer27 1995 31% 61 32 
 
Grace28 1996 50% 31 52 
 
Hoff29 1996 14% 30 12 
 
Wilson30 1996 73% 100 48 
All improved within 1 week but 
followed  weekly X 18 weeks the 
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every 3 months for 18 months 
Aymard31 1997 100% 7 
 
4-38 months follow-up 
Conley32 1997 68% 50 
 
Mean follow up 75 weeks  
All responders responded within 8 
weeks 
Aitchison33 1997 85% 26 
  
Rosenheck34 1996 57% 205 52 
Hospital days reduced from 168.1 to 
143.8 
Blieden35 1998 52% 33 26 
 
Luchins36 1998 75% 28 
 
Cost study, hospital days reduced 
from 23.5 to 7.6 
Sajatovic37 1998 30% 97 60 
 
Buckman38 1999 47% 518 60 Cost Study 
Percudani39 1999 80% 15 52 Cost Study 
Rosenheck40 1999 39% 122 26 Response at 26 weeks 
Simpson41 1999 19% 48 
 
48 completed 16 weeks, 36 went on 
to 2nd and 3rd 16week trials at other 
doses 
Dettling42 2000 81% 26 10 
 
Sajatovic43 2000 58% 522 60 
 
Wahlbeck44 2000 50% 10 10 50% dropout 
Kane45 2001 57% 37 29 
 
Narendran46 2003 67% 9 6 
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Honer47 2006 26% 34 8 Already clozapine poor responders 
Semiz48 2007 56% 97 16 
 Pooled Total                           
51% 2571 
*calculate SD from p<0.001 
 
Online Supplemental Material 
Table 2: Studies excluded from meta-regression 
Author Year Response 
% 
Total Trial 
Length(wks) 
Comments 
Kahn49 1993 47% 19 5 
8 responders 11 non-responders all 
improved 
Jonsson50 1995 70% 21 78 
15 patients showed “substantial 
response” 
Kronig51 1995 40.5% 45 6 
“responders” more likely to have 
serum concentration >350ng/ml 
VanderZwaag52 1996 * 28 12 
39% (18) low; 61% (23) med; 60% 
(15) high concentration groups 
responded 
Lindenmayer53 1998 * 35 12 No overall response metric 
Semyak54 2001 * 1415 36 
Response rate not defined 
Unclear if treatment-resistant 
schizophrenia population 
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Umbricht55 2002 59% 37 29 
Secondary analysis of patients in 
Kane trial45 
Saccchetti56 2009 * 74 18 
Significant response noted on 
PANSS but no response rate for 
treatment-resistant schizophrenia 
(n=65) 
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Online Supplemental Material 
Table 3: Inpatient hospital days with clozapine use+ 
Author Year Clozapin
e (N) 
Clozapine 
Inpatient Days 
(SD) 
Comparato
r 
(N) 
Comparator 
Inpatient 
Days 
(SD) 
Aitchison33* 1997 26 6.5 ± 6.5 26 39.5 ± 39.5 
Ghaemi68 1998 20 4.6 ± 11.3 20 47.7 ± 20 
Rosenheck34
* 
1996 205 143.8 ± 143.8 218 168.1 ± 168.1 
Luchins36 1998 28 7.6 ± 14.9 28 23.5 ± 49.6 
Buckman38* 1999 243 70.8 ± 70.8 243 152.9 ± 152.9 
Percudani39* 1999 12 58.8 ± 58.8 12 107.8 ± 58.8 
Atkinson69 2007 23 74.1 ± 137.3 23 119.8 ± 143.5 
+ SD assumed to equal the mean inpatient days if not otherwise specified  
*calculate SD from p<0.001 
 
